Cancer reports最新文献

{"title":"Exploitation of Biocomputational Approaches for siRNA-Mediated Gene Silencing of HPV: A Novel Therapeutic Strategy for Cervical Cancer","authors":"Md. Habib Ullah Masum,&nbsp;Rehana Parvin,&nbsp;Homaira Pervin Heema,&nbsp;Aklima Akter,&nbsp;Jannatul Ferdous","doi":"10.1002/cnr2.70434","DOIUrl":"10.1002/cnr2.70434","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>With recurrent high-risk human papillomavirus (HPV) infections, especially HPV16 and HPV18, cervical cancer is the fourth most common disease among women. The functional alterations of the E6 and E7 proteins are essential to the oncogenic process of high-risk HPVs and cervical cancer development.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The objective of this research is to design highly targeted and efficient small interfering RNAs (siRNAs) that target both HPV16 and HPV18, employing cutting-edge computational approaches to enhance therapeutic potential through a systematic bioinformatics-driven approach.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>This study utilized the i-Score Designer to identify and evaluate four potential small interfering RNAs (siRNAs) (E6_69, E6_451, E7_66, and E7_193) based on various algorithm criteria, including Ui-Tei, Amarzguioui, i-Score, and Reynolds scores. Consequently, a docking analysis was conducted to elucidate the intermolecular interactions between the RNA-induced silencing complex (RISC) proteins and the designed siRNAs. All siRNAs passed the recommended cutoff values, indicating a strong potential for gene silencing. Thermodynamic and structural analyses revealed that the designed siRNAs had favrable melting temperatures and free energies, suggesting adequate stability for effective gene silencing. Further, docking analysis demonstrated significant binding affinities and interaction profiles with the major RISC proteins (Dicer, Ago2, TRBP). The E6_69 and E7_193 significantly showed strong binding and intermolecular interactions, especially with Ago2, highlighting the potential for HPV gene silencing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The study revealed the potential of the designed siRNAs in silencing the E6 and E7 genes and their therapeutic applications against HPV. Future research should focus on validating these findings across various experiments, both in vivo and in vitro, and exploring alternative delivery approaches to enhance therapeutic efficacy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12703009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145755447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Radiotranscriptomic Approach to Analyze Combined Sets of T3b Stage-Specific Genes and Radiomic Features in Prostate Cancer","authors":"Qian Yang,&nbsp;Peng Tang,&nbsp;Jiao Mo,&nbsp;Qiuyang Li,&nbsp;Jiahui Huang,&nbsp;Xiaoyu Han,&nbsp;Hao Xu,&nbsp;Xi Liu,&nbsp;Jie Tang","doi":"10.1002/cnr2.70391","DOIUrl":"10.1002/cnr2.70391","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Current clinical staging of prostate cancer (PCa) using the tumor-node-metastasis (TNM) system and serum biomarkers remains limited in distinguishing locally advanced (T3b) PCa from organ-confined (T2c) disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Building on our previous biomarker discovery in differentiating PCa from that of benign prostatic hyperplasia, this study pioneers a radiotranscriptomic model to distinguish T3b stage PCa from T2c stage PCa by integrating contrast-enhanced ultrasound (CEUS) radiomics with stage-specific transcriptomic signatures, addressing a critical knowledge gap in precision staging.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>This prospective study was approved by the review board of Chinese PLA General Hospital (S2021-565-01), and all participants provided written informed consent. Transrectal B-mode ultrasound images and contrast-enhanced ultrasound images on two imaging planes were prospectively analyzed in 48 patients with biopsy-confirmed PCa (35 patients with stage T2c and 13 with stage T3b). Textural features were evaluated using microvascular ultrasonography and contrast-enhanced ultrasound. Radiomic data were then retrieved from all modes. An across-the-board investigation of mRNA and miRNA expressions was also performed in the two PCa stages. Six biomarkers (frizzled 4, ribosomal protein S7, ribosomal protein L29, miR-374c, miR-9, and miR-6510) were identified to differentiate T3b stage from T2c stage. The area under the curve (AUC) values of the combined set (AUC = 0.887, 0.956, and 0.996 for random forest, naïve Bayes, and support vector machine, respectively) and radiomic features alone (AUC = 0.921, 0.957, and 0.998, respectively) were found to be more accurate than those of the transcriptomic data alone (AUC = 0.583, 0.716, and 0.898, respectively) or clinical features alone (AUC = 0.585, 0.675, and 0.953, respectively). The PCa gene regulatory network comprised of four miRNAs (miR-148, miR-141, miR-342, and miR-210) may contribute to accelerating tumor progression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We established the new radiotranscriptomic signatures specifically optimized for differentiating T3b stage from T2c stage by decoding stage-specific imaging-genomic crosstalk. This new approach may overcome TNM staging limitations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70391","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145740814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of Radiofrequency Ablation in Treating Nonmetastatic Medullary Thyroid Carcinoma: A Case Study","authors":"Hojat Ebrahiminik,&nbsp;Hossein Chegeni,&nbsp;Haleh Chehrehgosha","doi":"10.1002/cnr2.70419","DOIUrl":"10.1002/cnr2.70419","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Radiofrequency ablation (RFA) can be an alternative management method for patients who are not candidates for surgery or who refuse it. There are limited data concerning the role of RFA in patients with medullary thyroid carcinoma (MTC). This case is presented to discuss the efficacy of RFA in the management of nonmetastatic MTC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>In this report, we present the case of an 83-year-old male with MTC who refused thyroidectomy. RFA was performed and he was followed for 1 year. In this case, RFA resulted in significant reductions in tumor size and calcitonin levels without any significant complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This research indicates that Radiofrequency Ablation (RFA) can yield acceptable results in the management of Medullary Thyroid Cancer (MTC). However, ongoing investigation remains crucial to clarify long-term outcomes and to compare RFA's efficacy against conventional management methods.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12690977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145713424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Myeloid Leukemia Secondary to Radiation Therapy for Rectal Cancer: A Case Report","authors":"Ahmad Alkhaledi,&nbsp;Laila Alhaj Hussaen,&nbsp;Linda Kahla,&nbsp;Baraa Sammoud,&nbsp;Suha Giselle Ghanem","doi":"10.1002/cnr2.70379","DOIUrl":"10.1002/cnr2.70379","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Therapy-related AML (t-AML) is a subtype of acute myeloid leukemia (AML) that arises in the bone marrow and primarily affects white blood cells. It is associated with prior exposure to cytotoxic agents, including chemotherapy and radiotherapy. The risk of the disease increases with age and treatment intensity. Although t-AML represents 25%–30% of all AML cases, its occurrence following radiotherapy is relatively rare. Diagnosis is confirmed via bone marrow biopsy, with differential diagnoses including other leukemias, lymphomas, and myelodysplastic syndromes. Prognosis is generally poor. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most effective curative option, though elderly patients often have limited eligibility due to comorbidities and poor performance status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>Five years after treatment for stage IIA rectal cancer, including radiotherapy, chemotherapy, and surgery, a 77-year-old male smoker presented with fatigue, weight loss, progressive dyspnea, headache, dizziness, blurred vision, and melena. Physical examination revealed pallor, purpura, skin crusts, and pustules. Laboratory findings showed anemia, thrombocytopenia, and circulating blasts. Bone marrow biopsy confirmed lymphoid infiltration. He was diagnosed with therapy-related AML (t-AML). Despite receiving three cycles of Azacitidine, he died of septic shock 7 months later.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case highlights the rare development of therapy-related acute myeloid leukemia in a colorectal cancer survivor following combined pelvic radiation and capecitabine plus oxaliplatin (CAPOX) chemotherapy, underscoring the importance of long-term hematologic surveillance in such patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12687298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145707286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Objective Assessment of Physical Activity in Breast Cancer Survivors: Associations With Adiposity and Metabolic Parameters of Glucose and Insulin—Insights From NHANES”","authors":"","doi":"10.1002/cnr2.70424","DOIUrl":"10.1002/cnr2.70424","url":null,"abstract":"<p>J. J. Cao-Alvira, E. F. Luciano, M. Sauane, and C. de la Parra, “Objective Assessment of Physical Activity in Breast Cancer Survivors: Associations With Adiposity and Metabolic Parameters of Glucose and Insulin—Insights From NHANES,” <i>Cancer Reports</i> 8, no. 9 (2025): e70339, https://doi.org/10.1002/cnr2.70339.</p><p>In the published article, affiliation 5 is incomplete. It currently reads:</p><p>5 City University of New York, New York, New York, USA</p><p>It should read:</p><p>5 Ph.D. Programs in Biochemistry and Biology, The Graduate Center, City University of New York, New York, New York, USA</p><p>We apologize for this error.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12687562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145707336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two Cases of Epidermal Growth Factor Receptor L861R Mutation-Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib","authors":"Kei Kagawa,&nbsp;Takeshi Masuda,&nbsp;Kiyofumi Shimoji,&nbsp;Kakuhiro Yamaguchi,&nbsp;Shinjiro Sakamoto,&nbsp;Yasushi Horimasu,&nbsp;Taku Nakashima,&nbsp;Hiroshi Iwamoto,&nbsp;Hironobu Hamada,&nbsp;Noboru Hattori","doi":"10.1002/cnr2.70420","DOIUrl":"10.1002/cnr2.70420","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Epidermal growth factor receptor (EGFR) mutations are detected in approximately 40%–50% of patients with lung adenocarcinoma in Asian populations and in around 10% of patients in Western populations. Among these, the EGFR L861R mutation is uncommon and undetectable using conventional polymerase chain reaction methods. Recently, clinically available next-generation sequencing (NGS) has been used to detect L861R mutations, potentially increasing the number of identified cases of L861R-positive non-small cell lung cancer. Herein, we present two cases of EGFR L861R-mutated lung adenocarcinoma treated with afatinib and osimertinib to evaluate the clinical efficacy and tolerability of these targeted therapies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>Case 1: A 63-year-old man with lung adenocarcinoma harboring an EGFR L861R mutation (cStage IVB) received afatinib 40 mg/day. Computer tomography (CT) on Day 49 showed shrinkage of the primary tumor, accompanied by a decrease in tumor markers. The afatinib dose was reduced to 30 mg/day due to Grade 1 diarrhea and an acneiform rash. Ground-glass opacities were subsequently observed around the tumor. Although pneumonitis was initially suspected, the findings were subsequently considered consistent with carcinomatous lymphangitis. Consequently, afatinib was discontinued on Day 56. Case 2: An 83-year-old man with lung adenocarcinoma harboring an EGFR L861R mutation (cStage IVB) received osimertinib 80 mg/day. Afatinib was avoided due to concerns regarding tolerability in the elderly. CT imaging on Day 14 showed tumor shrinkage with reduced attenuation and decreased levels of tumor markers. However, osimertinib was discontinued on Day 104 due to a Grade 3 skin rash. The response to osimertinib was evaluated as stable disease. Following treatment discontinuation, the disease progressed to multiple brain metastases, and supportive care was initiated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Here, we present the first case showing the anti-tumor efficacy of afatinib and the second case showing the anti-tumor efficacy of osimertinib in a patient with EGFR L861R-positive lung adenocarcinoma. Despite their short treatment durations, afatinib and osimertinib may have potential clinical activity in patients with EGFR L861R-positive lung cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70420","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic Ultrasound-Guided Tissue Acquisition for Breast Cancer Liver Metastases Enables the Detection of Biomarkers Essential for Treatment","authors":"Yuichi Takano,&nbsp;Naoki Tamai,&nbsp;Masataka Yamawaki,&nbsp;Jun Noda,&nbsp;Tetsushi Azami,&nbsp;Fumitaka Niiya,&nbsp;Naotaka Maruoka,&nbsp;Tatsuya Yamagami,&nbsp;Masatsugu Nagahama","doi":"10.1002/cnr2.70414","DOIUrl":"10.1002/cnr2.70414","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Evaluating biomarkers, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), in pathological specimens is crucial for guiding breast cancer treatment. Since biomarker expression may differ between primary and metastatic lesions, biopsy of metastatic sites is recommended whenever feasible. The liver is a common metastatic site for breast cancer, and percutaneous biopsy has traditionally been the standard approach. Recently, endoscopic ultrasound-guided tissue acquisition (EUS-TA) has emerged as an alternative method for sampling focal liver lesions. However, the utility of EUS-TA in assessing breast cancer biomarkers remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To evaluate the diagnostic performance of EUS-TA, including its ability to assess biomarkers in liver metastases from breast cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This single-center, retrospective observational study included patients who underwent EUS-TA for breast cancer liver metastases between 2016 and 2023. Clinical characteristics and specimen adequacy were analyzed. A pathologist classified the obtained tissue samples into four categories: (A) insufficient for diagnosis, (B) diagnosis possible only at the cytology level, (C) histological evaluation possible, but additional immunostaining for biomarkers not feasible, and (D) histological evaluation and additional immunostaining for biomarkers feasible.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifteen cases were included, with a median patient age of 68 years (all female). The median liver lesion size was 20 mm (range: 8–50 mm). The lesions were located in the left lobe in 12 cases and the right lobe in 3 cases. A 22G needle was used in 14 cases, while a 25G needle was used in 1 case. Specimen adequacy was classified as follows: category A in 1 case (6.6%), B in 2 cases (13.3%), C in 0 cases (0%), and D in 12 cases (80%). Biomarker evaluation was feasible in the majority of cases. No procedure-related adverse events were observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>EUS-TA is a valuable method for obtaining tissue samples from breast cancer liver metastases, enabling biomarker assessment in most cases.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70414","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Rare Upper Thoracic and Cervical Esophageal GIST Resected Through Thoracoscopic Esophageal Mobilization and a Cervical Approach: A Case Report","authors":"Kenjiro Ishii,&nbsp;Erica Nishimura,&nbsp;Yuki Tajima,&nbsp;Kumiko Hongo,&nbsp;Hiroto Fujisaki,&nbsp;Motohito Nakagawa,&nbsp;Kiminori Takano,&nbsp;Osahiko Hagiwara,&nbsp;Toshiyuki Enomoto,&nbsp;Takaharu Kiribayashi,&nbsp;Koji Asai,&nbsp;Takuya Nagata,&nbsp;Manabu Watanabe,&nbsp;Yoshihisa Saida","doi":"10.1002/cnr2.70423","DOIUrl":"10.1002/cnr2.70423","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm arising from the digestive tract; however, esophageal GIST is a very rare entity and represents &lt; 1% of all GIST cases. Furthermore, esophageal GIST is most commonly located in the lower esophagus, while esophageal GIST in the upper esophagus is rare among them. Therefore there are very few reports regarding their resection methods.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>This report describes a very rare resectable case of large upper esophageal GIST that extended to the cervical esophagus to be completely resected by performing thoracoscopic mobilization of the esophagus, followed by transection of the cervical esophagus via a cervical approach. The operative procedure was as follows: ensuring an adequate macroscopic margin for esophageal resection from within the thoracic cavity was judged to be difficult; therefore, only dissection of the thoracic and cervical esophagus was performed with thoracoscopic procedure, and the cervical esophagus was resected via a cervical approach. The abdominal procedure was carried out laparoscopically, and the specimen, including the tumor, was extracted from a small incision. Next, reconstruction using a gastric tube via a retrosternal approach was done. We also describe a literature review of upper esophageal GISTs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The surgical approach of large tumors of the upper thoracic and cervical esophageal GIST, including esophageal resection and reconstruction methods, needs to be carefully considered in advance. A cervical approach for esophageal resection is considered useful when it is difficult to resect the tumor's proximal end within the thoracic cavity safely.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70423","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV-Related Pelvic Squamous Cell Carcinoma of Unknown Primary: Two Case Studies","authors":"Sepideh Soltani,&nbsp;Sahar Dashti,&nbsp;Maryam Garousi,&nbsp;Elahe Mirzaee,&nbsp;Majid Kaheh,&nbsp;Masoome Zolfaghari,&nbsp;Maryam Abolhasani,&nbsp;Alireza Nikoofar","doi":"10.1002/cnr2.70402","DOIUrl":"10.1002/cnr2.70402","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cancer of unknown primary (CUP) presents diagnostic and management challenges, particularly when associated with rare subsets such as pelvic squamous cell carcinoma (SCC) of unknown primary origin. Human papillomavirus (HPV) is increasingly recognized as a prognostic and potentially predictive biomarker. HPV-associated SCCs often demonstrate better response to treatment and improved outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Cases</h3>\u0000 \u0000 <p>We present two cases of pelvic SCC with unknown primary origin, both positive for HPV genotype 16. Case 1 involved a 54-year-old woman with persistent abdominal pain who was diagnosed with an infiltrative 110 × 100 × 65 mm tumoral mass on the right side of the pelvic cavity, significantly involving the right iliac bone and right iliopsoas muscle; despite chemotherapy, the patient developed metastases. Case 2 featured a 46-year-old woman with progressive left lower limb pain, whose pelvic SCC was incidentally discovered on imaging with an 80 × 75 mm mass with an abnormal signal in the left iliac bone with extension to the left iliopsoas muscle involving the lower aspect of the iliopsoas muscle, and also involving the anterior aspect of the left sacral bone. She achieved a complete response to chemotherapy and chemoradiotherapy, with no evidence of recurrence during follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>HPV-associated pelvic SCC of unknown primary presents both diagnostic complexity and therapeutic opportunity. The detection of HPV genotype 16 in both cases supports a growing body of case-based evidence suggesting a potential association with a favorable prognosis. However, further studies are needed to clarify its role in guiding management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12674908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographics, Clinical Characteristics, and a Stage-Based Analysis of Treatments and Outcomes for Squamous Cell Carcinoma of the Penis","authors":"George M. Edwards,&nbsp;Lucas W. Ashley,&nbsp;Austin Holmes,&nbsp;Andrew W. Ju,&nbsp;Arjun Bhatt,&nbsp;Michael C. Larkins","doi":"10.1002/cnr2.70383","DOIUrl":"10.1002/cnr2.70383","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Penile squamous cell carcinoma (PSCC) is the most common penile cancer, accounting for ≥ 95% of cases, though it accounts for &lt; 1% of all malignancies in men in the United States. We report an updated, stage-stratified analysis of the efficacy of surgery, radiation, and chemotherapy, including adjuvant and neoadjuvant chemoradiation, with further analysis of demographic and clinical factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using the Surveillance, Epidemiology, and End Results (SEER) database, patients with PSCC diagnosed between 2000 and 2018 were identified. Five-year overall survival Cox regression analysis as well as univariate Kaplan–Meier analysis were performed, stratified by demographic and treatment variables.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Two thousand seven hundred eight patients with PSCC were identified, with 57.8% being older than 65 years at diagnosis and 94.2% undergoing surgical intervention. With multivariate analysis, increasing disease stage (<i>p</i> &lt; 0.001), age &lt; 65 years (<i>p</i> &lt; 0.001), lower disease grade (<i>p</i> &lt; 0.001) were all associated with increased survival, while treatment with chemotherapy or radiotherapy was both associated with decreased survival (<i>p</i> = 0.002 and &lt; 0.001, respectively). On univariate analysis, less invasive surgery was associated with increased survival among patients with low-grade, local (<i>p</i> &lt; 0.001) or regional (<i>p</i> = 0.03) disease. Among those with high-grade disease, local excision was associated with increased survival (<i>p</i> = 0.008), though among those with regional disease no survival difference was seen (<i>p</i> = 0.86). Patients with regional disease saw increasing survival with four or more lymph nodes dissected (69% vs. 61%, respectively; <i>p</i> = 0.002).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Surgical management of penile SCC remains the mainstay treatment, and less invasive surgery is associated with noninferior or improved 5-year overall survival regardless of disease stage and grade. Patients with regional disease had increased survival when four or more lymph nodes were dissected. Future analysis of these trends stratified by disease subhistology and more granular analysis of the role of lymphadenectomy are warranted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12674586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}